{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:53:08Z","timestamp":1791273188777,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03162-3","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:20:43Z","timestamp":1791271243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measurable residual disease-guided, fixed-duration, potentially definitive therapy for standard risk newly diagnosed multiple myeloma"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai R.","family":"Dholaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-4303","authenticated-orcid":false,"given":"Eva","family":"Medvedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1086","authenticated-orcid":false,"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly N.","family":"Godby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8919","authenticated-orcid":false,"given":"Susan","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-2640","authenticated-orcid":false,"given":"Timothy","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca W.","family":"Silbermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3162_CR1","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43:2739\u201351.","journal-title":"J Clin Oncol"},{"key":"3162_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1182\/blood.2024027674","volume":"146","author":"S Giri","year":"2025","unstructured":"Giri S, Dhakal B, Callander NS, Medvedova E, Godby K, Dholaria BR, et al. Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma. Blood. 2025;146:707\u201316.","journal-title":"Blood"},{"key":"3162_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/bjh.70359","volume":"208","author":"P Venkatesh","year":"2026","unstructured":"Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, et al. Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant. Br J Haematol. 2026;208:1001\u20138.","journal-title":"Br J Haematol"},{"key":"3162_CR4","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/bloodadvances.2025018537","volume":"10","author":"KH Maclachlan","year":"2026","unstructured":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, et al. IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM. Blood Adv. 2026;10:2616\u201325.","journal-title":"Blood Adv"},{"key":"3162_CR5","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013e901.","journal-title":"Lancet Haematol"},{"key":"3162_CR6","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770\u201381.","journal-title":"N Engl J Med"},{"key":"3162_CR7","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782\u201391.","journal-title":"N Engl J Med"},{"key":"3162_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906\u201317.","journal-title":"N Engl J Med"},{"key":"3162_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895\u2013905.","journal-title":"N Engl J Med"},{"key":"3162_CR10","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"3162_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa2600157","volume":"395","author":"S Kumar","year":"2026","unstructured":"Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, et al. Continuous or fixed-duration maintenance therapy in multiple myeloma. N Engl J Med. 2026;395:221\u201332.","journal-title":"N Engl J Med"},{"key":"3162_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood.2024027620","volume":"146","author":"J Corre","year":"2025","unstructured":"Corre J, Vincent L, Moreau P, Hebraud B, Hulin C, Bene MC, et al. Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results. Blood. 2025;146:679\u201392.","journal-title":"Blood"},{"key":"3162_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28\u201335.","journal-title":"JAMA Oncol"},{"key":"3162_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139:492\u2013501.","journal-title":"Blood"},{"key":"3162_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1182\/blood.2025029999","volume":"147","author":"A Schavgoulidze","year":"2026","unstructured":"Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, et al. High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing. Blood. 2026;147:266\u201375.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03162-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03162-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03162-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:20:44Z","timestamp":1791271244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03162-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":15,"alternative-id":["3162"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03162-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BRD: Institutional research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovirm Adicet, BMS, Molecular templat. Consultancy\/Advisor. BD: honoraria and served as a consultant and on the Speakers Bureau for Arcellx, Genentech, GSK, Janssen, Karyopharm, Pfizer, Sanofi, MJH BioScience, Janssen, ADC therapeutics, Gilead\/Kite, Autotus, Poseida, Accrotech. SB: research funding from Bristol Myers Squibb, AbbVie, Beigene, Fate Therapeutics and honoraria from AbbVie, Adaptive Biotechnologies, Bristol Myers Squibb, Janssen, Pfizer, AstraZeneca, Kite\/Arcellx and MJH Life sciences. RWS: consultant or in an advisory role for Sanofi-Aventis, Janssen Oncology, and Oncopeptides; and received research funding from Sanofi. LCJ: Honoraria from Amgen, Bristol-Myers-Squibb, AbbVie, Pfizer, Johnson & Johnson, Adaptive Biotechnologies, Sanofi, Genentech\/Roche, and research funding from Amgen, Bristol-Myers-Squibb, Johnson & Johnson, AbbVie, Caribou, Gracell, and Genentech\/Roche. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}